LEGN (Legend Biotech) Other Stockholders Equity: $77 Mil (As of Mar. 2026)


LEGN Legend Biotech Corp LEGN
74 GF Score
Price $29.93
GF Value $99.21
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Legend Biotech Other Stockholders Equity?

Legend Biotech LEGN -0.03% 74 Other Stockholders Equity is $77 Mil as of Mar. 2026. GuruFocus rates LEGN with a GF Score™ of 74/100 and a GF Value™ of $99.21 (Possible Value Trap). The stock has 3 warning signs investors should review.

Legend Biotech's Other Stockholders Equity for the quarter that ended in Mar. 2026 was $77 Mil.

Legend Biotech's quarterly Other Stockholders Equity increased from Sep. 2025 ($85 Mil) to Dec. 2025 ($88 Mil) but then declined from Dec. 2025 ($88 Mil) to Mar. 2026 ($77 Mil).

Legend Biotech's annual Other Stockholders Equity increased from Dec. 2023 ($55 Mil) to Dec. 2024 ($74 Mil) and increased from Dec. 2024 ($74 Mil) to Dec. 2025 ($88 Mil).

Legend Biotech Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Legend Biotech's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Legend Biotech Other Stockholders Equity Chart

Legend Biotech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial 19.70 39.05 54.62 74.40 88.00

Legend Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 74.95 72.37 84.74 88.00 76.80
LEGN
74GF Score
Legend Biotech Corp LEGN
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Legend Biotech Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $77 Mil mean?
Legend Biotech (LEGN) has a Other Stockholders Equity of $77 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Legend Biotech and its competitors.
Is Legend Biotech's Other Stockholders Equity too high?
Legend Biotech's current Other Stockholders Equity is $77 Mil. Overall, Legend Biotech has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Legend Biotech's Other Stockholders Equity compare to TVTX and ORKA?
Legend Biotech's Other Stockholders Equity of $77 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Legend Biotech and its competitors. Legend Biotech's current Other Stockholders Equity is $77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Legend Biotech stock overvalued right now?
Based on GuruFocus' analysis, Legend Biotech (LEGN) is currently considered Possible Value Trap. The stock's GF Value™ is $99.21, compared to a current price of $29.93 — trading 69.8% below its estimated fair value. The current Other Stockholders Equity is $77 Mil. Legend Biotech's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Legend Biotech (LEGN), the current Other Stockholders Equity is $77 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Legend Biotech (LEGN) Overvalued in 2026?

Based on GuruFocus' analysis, Legend Biotech stock appears to be undervalued. The current stock price of $29.93 is trading 69.8% below its estimated GF Value™ of $99.21. GuruFocus considers Legend Biotech to be Possible Value Trap.

Key valuation signals for LEGN:

  • Other Stockholders Equity: $77 Mil
  • GF Value™: $99.21 vs. price of $29.93 (69.8% below fair value)
  • GF Score™: 74/100 with 3 warning signs

No single metric tells the full story. See the LEGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Legend Biotech Business Description

Other Exchanges 9LB:Germany
Address 2101 Cottontail Lane, Somerset, NJ, USA, 08873
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
74GF Score

Get the complete analysis for LEGN

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.93
Price
$99.21
GF Value